Targeting Drug-Resistance In Paediatric Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$649,048.00
Summary
Leukaemia is the most common type of cancer in children but resistance to therapy continues to be a significant problem. This project will investigate the biology of drug-resistance and relapse using a mouse model that replicates the human disease. We hope to identify novel therapeutic targets that can be used in combination with existing therapies to improve outcomes in this disease, particularly for patients that develop drug-resistance such as those at the time of relapse.
C-Cbl-directed Leukaemogenesis: The Roles Of Core-Binding Factors And PI 3-kinase Signalling.
Funder
National Health and Medical Research Council
Funding Amount
$636,199.00
Summary
Myeloid leukaemia remains a major health problem with only about one third of patients being cured. More effective treatments are therefore needed. For these treatments to be developed more knowledge is required about the genetic and biochemical changes that cause myeloid leukaemia. This project aims to increase this knowledge by studying how cancer-causing proteins are involved in the development of myeloid leukaemia and how targeting these proteins can be used to develop new treatments.